中华肿瘤杂志 2026 年6 月第 48 卷第 6 期 Chin J Oncol, June 2026, Vol. 48, No. 6儿童青少年非霍奇金淋巴瘤诊治专家共识(2026版)中华医学会肿瘤学分会淋巴瘤学组通信作者:张翼鷟,中山大学肿瘤防治中心儿童肿瘤科 华南恶性肿瘤防治全国重点实验室 广东省恶性肿瘤临床医学研究中心,广州 510060,Email:zhangyzh@sysucc.org.cn;鞠秀丽,山东大学齐鲁医院儿科,济南 250012,Email:shellysdcn@126.com;段彦龙,国家儿童医学中心 首都医科大学附属北京儿童医院儿童肿瘤中心肿瘤内科 儿童血液病与肿瘤分子分型北京市重点实验室 儿童肿瘤国家临床重点专科 儿科重大疾病研究教育部重点实验室,北京 100045,Email:duanyanlong@hotmail.com【摘要】 非霍奇金淋巴瘤(NHL)是常见的儿童恶性肿瘤,约占所有儿童恶性肿瘤的 7%,在青少年中发病率更高。经过规范治疗,总生存率超过 80%。淋巴母细胞性淋巴瘤(LBL)、成熟 B 细胞非霍奇金淋巴瘤(mB-NHL)和间变性大细胞淋巴瘤(ALCL)占儿童和青少年 NHL 的 90%。中华医学会肿瘤学分会淋巴瘤学组组织儿童肿瘤科、儿科、内科、病理科、影像科等多学科专家,依据国内外循证证据及临床经验广泛征集意见,针对儿童和青少年好发的非霍奇金淋巴瘤(包括 LBL、mB-NHL 和ALCL),在临床表现、辅助检查、病理诊断、临床分期和治疗方面凝练共识意见,以期为临床规范化治疗提供循证依据,进一步提高患者的生存率。【关键词】 非霍奇金淋巴瘤; 儿童; 青少年; 淋巴母细胞性淋巴瘤; 成熟 B细胞非霍奇金淋巴瘤; 间变性大细胞淋巴瘤; 共识实践指南注册:国际实践指南注册与透明化平台(PREPARE-2024CN357)Expert consensus on the diagnosis and treatment of non-Hodgkin lymphoma in children and adolescents (2026 edition) Lymphoma Group, Oncology Branch, Chinese Medical AssociationCorresponding authors: Zhang Yizhuo, Department of Pediatric Oncology, Sun Yat-sen University Can‐cer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, China, Email: zhangyzh@sysucc.org.cn; Ju Xiuli, Department of Pediat‐rics, Qilu Hospital of Shandong University, Jinan 250012, China, Email: shellysdcn@126.com; Duan Yan‐long, Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematol‐ogy Oncology, National Key Clinical Discipline of Pediatric Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China, Email: duanyanlong@hotmail.com【Abstract】 Non-Hodgkin lymphoma (NHL) is a common malignant tumor in children, accounting for approximately 7% of all childhood malignancies, with a higher incidence rate among adolescents. After standardized treatment, the overall survival rate exceeds 80%. Lymphoblastic lymphoma (LBL), mature B-cell non-Hodgkin lymphoma (mB-NHL), and anaplastic large cell lymphoma (ALCL) account for 90% of pediatric and adolescent NHL cases. The Lymphoma Group of the Oncology Branch of the Chinese Medical Association has organized multidisciplinary experts from pediatric oncology, pediatrics, internal medicine, pathology, and radiology. Based on domestic ·指南与共识·DOI:10.3760/cma.j.cn112152-20251015-00516收稿日期 2025-10-15 本文编辑 苏在明引用本文:中华医学...